SMO and acute myeloid leukemia: However, in previous work we could show that the treatment with the SMO inhibitor cyclopamine had no impact on the GLI promoter activity in AML reporter cell lines—leading to the hypothesis that the activation of GLI proteins in AML cells occurs independently of SMO [3].